Amyloidosis
![](https://www.ucl.ac.uk/medicine/sites/medicine/files/styles/owl_carousel/public/research-amyloidosis-nac-carousel.jpg?itok=FsiBb4Mg)
National Amyloidosis Centre
The NHS National Amyloidosis Centre is the only UK centre specialising in amyloidosis. We provide a diagnostic and management advice service for UK patients.
![](https://www.ucl.ac.uk/medicine/sites/medicine/files/styles/owl_carousel/public/heartbeat-carousel.jpg?itok=vakQ75ZI)
Patients with rare heart condition given lifeline
People diagnosed with a life-threatening cardiac condition have been given new hope, thanks to a ground-breaking new drug developed by UCL and the Royal Free Hospital.
![](https://www.ucl.ac.uk/medicine/sites/medicine/files/styles/owl_carousel/public/research-amyloidosis-lachmann-carousel.jpg?itok=6tLJ-iFZ)
Helen Lachmann elected Fellow of the Academy of Medical Sciences
Professor Lachmann, based at the Royal Free Hospital's National Amyloidosis Centre, said she was honoured to be elected to the Academy.
![](https://www.ucl.ac.uk/medicine/sites/medicine/files/styles/owl_carousel/public/research-amyloidosis-julian-gillmore-carousel.jpg?itok=sGBNjUcc)
NICE backs Alnylam's Amvuttra for rare ATTR amyloidosis
Alnylam's gene-silencing drug Amvuttra is set to be made available on the NHS in England and Wales, which Prof. Julian Gillmore describes as a "remarkable step forward".
Our work
Amyloidosis is a disorder of protein folding in which normally soluble proteins accumulate in the tissues as abnormal insoluble fibrils. These deposits damage the structure and function of the tissues and cause serious disease which is usually fatal if it affects major organs.
Our world-leading research covers all aspects of the pentraxin family of plasma proteins and amyloidosis. Our studies range from molecular, genetic, biochemical, physiological, and pathological investigations to clinical diagnostics, patient management and new drug discovery.
We also investigate inflammatory diseases and the major common diseases associated with local amyloid deposits: Alzheimer's disease and type 2 diabetes mellitus.
Professors, Readers, Lecturers and Consultants
![Professor Julian Gillmore](https://www.ucl.ac.uk/medicine/sites/medicine/files/styles/small_image/public/research-profile-amyloidosis-julian-gillmore.jpg?itok=GxyXix47)
Prof. Julian Gillmore
Head of Centre
![Professor Sir Mark Pepys](https://www.ucl.ac.uk/medicine/sites/medicine/files/styles/small_image/public/research-profile-amyloidosis-mark-pepys.jpg?itok=rAgzrGr8)
Prof. Sir Mark Pepys
Director, Wolfson Drug Discovery Unit
![Professor Vittorio Bellotti](https://www.ucl.ac.uk/medicine/sites/medicine/files/styles/small_image/public/research-profile-amyloidosis-vittorio-bellotti.jpg?itok=8R8uBchz)
Prof. Vittorio Bellotti
Emeritus Professor
![Professor Marianna Fontana](https://www.ucl.ac.uk/medicine/sites/medicine/files/styles/small_image/public/research-profile-amyloidosis-marianna-fontana.jpg?itok=4D_q9GJd)
Prof. Marianna Fontana
Professor of Cardiology
![Professor Philip Hawkins](https://www.ucl.ac.uk/medicine/sites/medicine/files/styles/small_image/public/research-profile-amyloidosis-philip-hawkins.jpg?itok=Uamiv1p7)
Prof. Philip Hawkins
Principal Clinical Research Fellow
![Professor Helen Lachmann](https://www.ucl.ac.uk/medicine/sites/medicine/files/styles/small_image/public/research-profile-amyloidosis-helen-lachmann.jpg?itok=R4Kp6SHi)
Prof. Helen Lachmann
Professor of Medicine
![Basic silhouette in a circle, in light grey](https://www.ucl.ac.uk/medicine/sites/medicine/files/styles/small_image/public/research-profile-roundel-lightgrey.jpg?itok=Gs3WD6WH)
Dr Paul Simons
Honorary Professor
![Professor Ashutosh Wechalekar](https://www.ucl.ac.uk/medicine/sites/medicine/files/styles/small_image/public/research-profile-amyloidosis-ashutosh-wechalekar.jpg?itok=j7v8F9Bo)
Prof. Ashutosh Wechalekar
Professor of Medicine & Haematology
![Dr Shameem Mahmood](https://www.ucl.ac.uk/medicine/sites/medicine/files/styles/small_image/public/research-profile-amyloidosis-shameem-mahmood.jpg?itok=N0qTvWMt)
Dr Shameem Mahmood
Consultant Haematologist
![Basic silhouette in a circle, in light grey](https://www.ucl.ac.uk/medicine/sites/medicine/files/styles/small_image/public/research-profile-roundel-lightgrey.jpg?itok=Gs3WD6WH)
Dr Ana Martinez-Naharro
Consultant Cardiologist
![Dr Carol Whelan](https://www.ucl.ac.uk/medicine/sites/medicine/files/styles/small_image/public/research-profile-amyloidosis-carol-whelan.jpg?itok=gMaU7DTe)
Dr Carol Whelan
Honorary Associate Professor
![Basic silhouette in a circle, in light grey](https://www.ucl.ac.uk/medicine/sites/medicine/files/styles/small_image/public/research-profile-roundel-lightgrey.jpg?itok=Gs3WD6WH)
Dr Sriram Ravichandran
Division of Medicine
Selected publications
- Kastritis E, Misra A, Gurskyte L, Kroi F, Verhoek A, Vermeulen J, Ammann E, Lam A, Cote S, Wechalekar AD. Assessing the prognostic utility of hematologic response for overall survival in patients with newly diagnosed AL amyloidosis: results of a meta-analysis. Hematology. 2023 Dec;28(1):2157581.
- Suzuki K, Wechalekar AD, Kim K, Shimazaki C, et al. Daratumumab plus bortezomib, cyclophosphamide, and dexamethasone in Asian patients with newly diagnosed AL amyloidosis: subgroup analysis of ANDROMEDA. Ann Hematol. 2023 Apr;102(4):863-876. Epub 2023 Mar 2.
- Rauf MU, Hawkins PN, ... Ravichandran S, Ioannou A, Patel R, Starr N, Hutt DF, Mahmood S, Wisniowski B, Martinez-Naharro A, Venneri L, Whelan C, Roczenio D, Gilbertson J, Lachmann HJ, Wechalekar AD, ... Fontana M, Gillmore JD. Tc-99m labelled bone scintigraphy in suspected cardiac amyloidosis. Eur Heart J. 2023 Mar 22:ehad139.
- Hatipoglu S, Wechalekar AD, Wechalekar K. Extensive cardiac FDG uptake in a patient with AL amyloidosis. J Nucl Cardiol. 2023 Mar 17:1-7.
- Wechalekar AD, Cibeira MT, Gibbs SD, Jaccard A, et al. Guidelines for non-transplant chemotherapy for treatment of systemic AL amyloidosis: EHA-ISA working group. Amyloid. 2023 Mar;30(1):3-17.
- Sanchorawala V, Wechalekar AD, Kim K, Schönland SO, et al. Quality of life and symptoms among patients with relapsed/refractory AL amyloidosis treated with ixazomib-dexamethasone versus physician's choice. Am J Hematol. 2023 Jan 28.
- Martinez-Naharro A, ... Ravichandran S, Brown J, Law S, Quarta C, Mahmood S, Wisniowski B, Pica S, Sachchithanantham S, Lachmann HJ, Moon JC, Knight DS, Whelan C, ... Gillmore JD, Hawkins PN, Wechalekar AD, Fontana M. Cardiovascular magnetic resonance in light-chain amyloidosis to guide treatment. Eur Heart J. 2022 Dec 1;43(45):4722-4735.
- Ravichandran S, Law S, Mahmood S, Wisniowski B, Foard D, Fontana M, Martinez-Naharro A, Whelan C, Hawkins PN, Gillmore JD, Lachmann HJ, Wechalekar AD. Long-term outcomes in light chain deposition disease-analysis of a UK cohort. Am J Hematol. 2022 Dec;97(12):E444-E446.
- Wechalekar AD, Sanchorawala V. Daratumumab in AL amyloidosis. Blood. 2022 Dec 1;140(22):2317-2322.
- Cohen OC, Blakeney IJ, Law S, Ravichandran S, Gilbertson J, Rowczenio D, Mahmood S, Sachchithanantham S, Wisniowski B, Lachmann HJ, Whelan CJ, Martinez-Naharro A, Fontana M, Hawkins PN, Gillmore JD, Wechalekar AD. The experience of hereditary apolipoprotein A-I amyloidosis at the UK National Amyloidosis Centre. Amyloid. 2022 Dec;29(4):237-244.
![The Amyloidosis / MRI Team with PPE masks at the Royal Free Hospital](https://www.ucl.ac.uk/medicine/sites/medicine/files/styles/non_responsive/public/research-mri-team-teaser.jpg?itok=m4aUSR4Y)
![The Amyloidosis Team 2020 in an office](https://www.ucl.ac.uk/medicine/sites/medicine/files/styles/non_responsive/public/amyloidosis-group-2020-teaser.jpg?itok=XVA5bzbI)
Funding and partnerships
Our research on amyloidosis and pentraxins received over £18 million from the Medical Research Council between 1969-2016, the longest continuous MRC support to an external researcher (Professor Sir Mark Pepys).
We have received substantial support from The Wolfson Foundation (almost £4 million), The Wellcome Trust (including a £3.8 million Seeding Drug Discovery Initiative Award) and other medical charities. Between 2012 and 2022, core support for the Wolfson Drug Discovery Unit was provided by the NIHR via the UCLH/UCL BRC.
Generous charitable donations by patients and their relatives and friends to the Amyloidosis Research Fund provides flexible non-earmarked resources which are immensely helpful to our fast-moving research.
![NIHR NIHR Logo](https://www.ucl.ac.uk/medicine/sites/medicine/files/styles/small_image/public/logo-nihr.png?itok=VY9RVXQM)
![Wellcome Trust Wellcome Trust logo](https://www.ucl.ac.uk/medicine/sites/medicine/files/styles/small_image/public/logo-wellcome-trust_0.png?itok=o09nW6S6)
![The logo for the URKI Medical Research Council. A quadrilateral, with 'UKRI' over navy on the left, and two teal portions on the right.](https://www.ucl.ac.uk/medicine/sites/medicine/files/styles/small_image/public/logo-medical-research-council.png?itok=z5QOzuqw)
![The Wolfson Foundation logo: features a red asterisk after 'Wolfson'.](https://www.ucl.ac.uk/medicine/sites/medicine/files/styles/small_image/public/logo-wolfson-foundation.png?itok=PU1BgUxO)
Awards
- 2007 - Professor Pepys awarded the Royal Society's GlaxoSmithKline Prize and Lecture.
- 2008 - Professor Pepys awarded the Ernst Chain Prize.
- 2012 - Professor Pepys receives a knighthood for services to biomedicine.
Contact
Telephone: Patient/Clinical Enquiries
Centre for Amyloidosis & Acute Phase Proteins
Division of Medicine (Royal Free Campus)
University College London
Rowland Hill Street
London
NW3 2PF
- The nearest London Underground station is Belsize Park.
- The nearest national rail station is Hampstead Heath (London Overground).
The Centre is on the Lower Third Floor of the Medical School. Access is via the lifts in the entrance hall of the Medical School on Rowland Hill Street.